Anti-PCSK9 therapies for the treatment of hypercholesterolemia (Q38067460)

28 August 2017

1 reference

title

Anti-PCSK9 therapies for the treatment of hypercholesterolemia (English)

1 reference

28 August 2017

0 references

Amanda J Hooper

1

1 reference

PubMed ID

23240807

28 August 2017

John R Burnett

series ordinal

2

1 reference

PubMed ID

23240807

28 August 2017

language of work or name

English

0 references

publication date

17 December 2012

1 reference

Expert Opinion on Biological Therapy

28 August 2017

1 reference

28 August 2017

13

1 reference

28 August 2017

429-435

1 reference

28 August 2017

3

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

The biology and therapeutic targeting of the proprotein convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Liver dysfunction and steatosis in familial hypobetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Abetalipoproteinemia: two case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

PCSK9: an emerging target for treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.748743

10.1517/14712598.2012.748743

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23240807